High-content assay multiplexing for toxicity screening in induced pluripotent stem cell-derived cardiomyocytes and hepatocytes

Assay and Drug Development Technologies

Volumn 13, Issue 9, 2015, Pages 529-546

  Grimm, Fabian Alexander ^a   Iwata, Yasuhiro ^a   Sirenko, Oksana ^b   Bittner, Michael ^c   Rusyn, Ivan ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b MOLECULAR DEVICES CORPORATION   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; AMIODARONE; CISAPRIDE; CRIZOTINIB; CYCLIC AMP; CYTOTOXIC AGENT; DOXORUBICIN; G PROTEIN COUPLED RECEPTOR; ISOPRENALINE; MENADIONE; PROPRANOLOL; REACTIVE OXYGEN METABOLITE; SOTALOL; SUNITINIB;

ARTICLE; CALCIUM TRANSPORT; CARDIOTOXICITY; CELL BASED HIGH CONTENT SCREENING ASSAY; CELL FUNCTION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; HEART MUSCLE CELL; HUMAN; HUMAN CELL; LIPID STORAGE; LIVER CELL; LIVER TOXICITY; PHENOTYPE; PLURIPOTENT STEM CELL; CARDIAC MUSCLE CELL; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; HIGH THROUGHPUT SCREENING; INDUCED PLURIPOTENT STEM CELL; METABOLISM; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; TOXICITY TESTING;

CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC; REACTIVE OXYGEN SPECIES; RECEPTORS, G-PROTEIN-COUPLED; TOXICITY TESTS;

EID: 84948147405     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2015.659     Document Type: Article

References (36)

1. McPartland J, Dantzker HC, Portier CJ. Building a robust 21st century chemical testing program at the U.S. Environmental Protection Agency: recommendations for strengthening scientific engagement. Environ Health Perspect 2015; 123: 1-5
2. Settivari RS, Ball N, Murphy L, Rasoulpour R, Boverhof DR, Carney EW. Predicting the future: opportunities, and challenges for the chemical industry to apply 21st-century toxicity testing. J Am Assoc Lab Anim Sci 2015; 54: 214-223
3. Landrigan PJ, Goldman LR. Chemical safety, health care costs, and the Affordable Care Act. Am J Ind Med 2014; 57: 1-3
4. Adeleye Y, Andersen M, Clewell R, et al. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment. Toxicology 2014; 332: 102-111
5. Dix DJ, Houck KA, Martin MT, Richard AM, Setzer RW, Kavlock RJ. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol Sci 2007; 95: 5-12
6. Tice RR, Austin CP, Kavlock RJ, Bucher JR. Improving the human hazard characterization of chemicals: a Tox21 update. Environ Health Perspect 2013; 121: 756-765
7. Xia M, Huang R, Witt KL, et al. Compound cytotoxicity profiling using quantitative high-throughput screening. Environ Health Perspect 2008; 116: 284-291
8. Sundberg SA. High-throughput, and ultra-high-throughput screening: solutionand cell-based approaches. Curr Opin Biotechnol 2000; 11: 47-53
9. An WF, Tolliday N. Cell-based assays for high-throughput screening. Mol Biotechnol 2010; 45: 180-186
10. Jennings P. The future of in vitro toxicology. Toxicol In Vitro 2014; 1217-1221
11. Singh VK, Kalsan M, Kumar N, Saini A, Chandra R. Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery. Front Cell Dev Biol 2015; 3: 1-18
12. Sirenko O, Crittenden C, Callamaras N, et al. Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells. J Biomol Screen 2013; 18: 39-53
13. Sirenko O, Cromwell EF, Crittenden C, Wignall JA, Wright FA, Rusyn I. Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity. Toxicol Appl Pharmacol 2013; 273: 500-507
14. Sirenko O, Hesley J, Rusyn I, Cromwell EF. High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells. Assay Drug Dev Technol 2014; 12: 43-54
15. Ma J, Guo L, Fiene SJ, et al. High purity human-induced pluripotent stem cellderived cardiomyocytes: electrophysiological properties of action potentials, and ionic currents. Am J Physiol Heart Circ Physiol 2011; 301: H2006-H2017
16. Guguen-Guillouzo C, Corlu A, Guillouzo A. Stem cell-derived hepatocytes, and their use in toxicology. Toxicology 2010; 270: 3-9
17. Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms, and potential cardioprotective therapies. J Am Heart Assoc 2014; 3: e000665
18. Njoku DB. Drug-induced hepatotoxicity: metabolic, genetic, and immunological basis. Int J Mol Sci 2014; 15: 6990-7003
19. Sturgill MG, Lambert GH. Xenobiotic-induced hepatotoxicity: mechanisms of liver injury, and methods of monitoring hepatic function. Clin Chem 1997; 43: 1512-1526
20. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009; 16: 3041-3053
21. Garside H, Marcoe KF, Chesnut-Speelman J, et al. Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells, and cryopreserved primary human hepatocytes. Toxicol In Vitro 2014; 28: 171-181
22. Germano D, Uteng M, Pognan F, Chibout SD, Wolf A. Determination of liver specific toxicities in rat hepatocytes by high content imaging during 2-week multiple treatment. Toxicol In Vitro 2014; pii: S0887-2333(14)00089-7
23. ASTM International: Standard Test Method for Determining Carcinogenic Potential of Virgin Base Oils in Metalworking Fluids. In E1687-10. ASTM International, West Conshohocken, PA, 2010. Available at www.astm.org/DATABASE.CART/HISTORICAL/E1687-10.htm (last accessed September 25, 2015
24. U.S. EPA: Benchmark Dose Technical Guidance. Risk Assessment Forum, US EPA: Washington, DC, 2012. Available at www2.epa.gov/osa/benchmark-dosetechnical-guidance (last accessed September 25, 2015
25. Gilbert N. Data gaps threaten chemical safety law. Nature 2011; 475: 150-151
26. Michelini E, Cevenini L, Calabretta MM, Calabria D, Roda A. Exploiting in vitro, and in vivo bioluminescence for the implementation of the three Rs principle (replacement, reduction, and refinement) in drug discovery. Anal Bioanal Chem 2014; 406: 5531-5539
27. Ferri N, Siegl P, Corsini A, Herrmann J, Lerman A, Benghozi R. Drug attrition during pre-clinical, and clinical development: understanding, and managing drug-induced cardiotoxicity. Pharmacol Ther 2013; 138: 470-484
28. Roberts RA, Kavanagh SL, Mellor HR, Pollard CE, Robinson S, Platz SJ. Reducing attrition in drug development: smart loading preclinical safety assessment. Drug Discov Today 2014; 19: 341-347
29. Casartelli A, Lanzoni A, Comelli R, et al. A novel, and integrated approach for the identification, and characterization of drug-induced cardiac toxicity in the dog. Toxicol Pathol 2011; 39: 361-371
30. Li X, Nooh MM, Bahouth SW. Role of AKAP79/150 protein in beta1-adrenergic receptor trafficking, and signaling in mammalian cells. J Biol Chem 2013; 288: 33797-33812
31. Doherty KR, Wappel RL, Talbert DR, et al. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol 2013; 272: 245-255
32. Berggren E, Amcoff P, Benigni R, et al. Chemical safety assessment using readacross: assessing the use of novel testing methods to strengthen the evidence base for decision making. Environ Health Perspect 2015 [Epub ahead of print] DOI: 10.1289/ehp.1409342
33. Briede JJ, van Delft JM, de Kok TM, et al. Global gene expression analysis reveals differences in cellular responses to hydroxyl-, and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci 2010; 114: 193-203
34. Donato MT, Martinez-Romero A, Jimenez N, et al. Cytometric analysis for druginduced steatosis in HepG2 cells. Chem Biol Interact 2009; 181: 417-423
35. Raja K, Thung SN, Fiel MI, Chang C. Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. Semin Liver Dis 2009; 29: 423-428
36. Antherieu S, Rogue A, Fromenty B, Guillouzo A, Robin MA. Induction of vesicular steatosis by amiodarone, and tetracycline is associated with upregulation of lipogenic genes in HepaRG cells. Hepatology 2011; 53: 1895-1905